Related Experiment Video

Updated: May 14, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity

Byung Hee Park1, Kyung Hee Jung, Sun-Mi Yun

  • 1Department of Biomedical Sciences, College of Medicine, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 400-712, Republic of Korea.

Cancer Letters
|January 24, 2013
PubMed

Insights

A novel compound, KRC-327, selectively inhibits the c-Met receptor tyrosine kinase, suppressing cancer cell growth and proliferation. This targeted therapy shows promise for treating human cancers driven by c-Met signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), play crucial roles in cancer development and metastasis.
  • Targeting aberrant c-Met signaling is a key strategy in cancer therapy.

Purpose of the Study:

  • To synthesize and evaluate a novel triazolopyridazine derivative, KRC-327, for its selective inhibition of c-Met.
  • To investigate the anti-cancer effects of KRC-327 in preclinical models.

Main Methods:

  • Receptor tyrosine kinases (RTKs) array to assess c-Met inhibition in cancer cells.
  • Immunofluorescence staining to confirm c-Met targeting.
  • Western blotting to analyze downstream signaling pathways (Gab1, Akt, STAT3, Erk).
  • Cell viability assays, cell cycle analysis, and functional assays (proliferation, migration, colony formation) in various cancer cell lines.
  • In vivo studies using xenograft animal models.

Main Results:

  • KRC-327 selectively inhibited activated c-Met in c-Met over-expressing cancer cells (MKN-45, SNU-638, SNU-5).
  • KRC-327 suppressed downstream signaling pathways and induced G0/G1 cell cycle arrest.
  • The compound inhibited proliferation, migration, and colony formation in ligand-stimulated cancer cells.
  • In vivo, KRC-327 delayed tumor growth and inhibited c-Met signaling and proliferation.

Conclusions:

  • KRC-327 demonstrates potent and selective inhibition of c-Met.
  • KRC-327 exhibits significant anti-cancer activity by inhibiting cell growth and proliferation.
  • KRC-327 represents a promising drug candidate for c-Met-targeted cancer therapy.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: